Theralase Technologies Inc. V.TLT

Sorry wrong Link last post :-(

[Oden6570]

Non-Muscle Invasive Bladder Cancer Market Set to Reach New Heights Amidst Growing Pipeline and Research Initiatives | DelveInsight

[wildbird1]

Oden6570. In the article you provided there is a sub-article. Sample page for NMIBC Market Outlook Report It is mentioned that in Japan Adstiladrin is expected to capture the largest market shares for BCG resistant patients. From what I read on this board Adstiladrin is a repeated treatment has contraindications and has a much lower CR% at 450 days than TLT treatment. Adstiladrin is absolutely

[Alamir1111]

That's a al generated article .They got thousand of that for sale or signing up .wildbird figured youre more sophisticated 

[Alamir1111]

Poor Birdie he's one of top cheerleaders  can't differentiate between bs and reality.But we appreciate his insights

[CancerSlayer]

In the US, it has been reported (per a web-based survey of urologic oncologists) that intravesical Gem/Doce (chemo) is also commonly used as a first-line bladder-sparing treatment (BST) for BCG-unresponsive NMIBC.  However, there were significant obstacles reported to prescribing this treatment, which included clinical workflow issues (i.e. frequent dosing = 6 weekly doses, followed by